Please login to the form below

Not currently logged in
Email:
Password:

German partners find diabetes biomarker

Helmholtz Zentrum München and Boehringer Ingelheim have identified a biomarker for diabetes-relevant protein

Helmholtz Zentrum München and Boehringer Ingelheim have jointly identified a biomarker for diabetes-relevant protein.

The indicator will enable the pre-clinical testing of FABP4 inhibitors, therefore facilitating the selection of potentially effective substances. Studies on human subjects and mouse models show that the FABP4 protein could be a potential target protein for new drugs to treat diabetes mellitus and atherosclerosis.

The biomarker was found through the use of lipidomics and metabolomics. Scientists at the Helmholtz Zentrum München were the first to use the modern lipidomics technologies to successfully identify such functionally relevant biomarkers for FABP4.

Boehringer Ingelheim provided the necessary biological and indication-specific knowledge; the Helmholtz Zentrum München contributed expertise in metabolomics and bioinformatics.

The development of the biomarker for FABP4 was the pilot project for the collaborative research venture to identify functional biomarkers.

19th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...